Cemiplimab in treating locally advanced NSCLC

Andrea Müllerová; Juraj Kultan

doi:10.36290/xon.2023.014

journal article Mar 01, 2023

Cemiplimab in treating locally advanced NSCLC

Andrea Müllerová Juraj Kultan

Onkologie Vol. 17 No. 1 pp. 62-66 · S. Karger AG

View at Publisher Save 10.36290/xon.2023.014

Topics

No keywords indexed for this article. Browse by subject →

References

16

[1]

(2022)

[2]

10.3747/co.27.6047

[3]

10.3747/co.27.6241

[4]

10.3389/fonc.2022.874022

[5]

10.2478/raon-2020-0026

[6]

10.21037/tlcr.2019.08.05

[7]

Committee "Enhancing NIH Research on Autoimmune Disease" Washington (DC): National Academies Press (US); May (2022)

[8]

10.21037/med-21-8

[9]

10.1016/j.jtho.2020.02.005

[10]

Pass HI (2014)

[11]

10.1016/s0959-8049(97)00377-8

[12]

10.1016/s0959-8049(00)00350-6

[13]

10.3109/0284186x.2012.718093

[14]

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş et al.

The Lancet 10.1016/s0140-6736(21)00228-2

[15]

10.1016/j.jtho.2021.08.217

[16]

10.1002/cncr.34477

Metrics

0

Citations

16

References

Details

Published: Mar 01, 2023
Vol/Issue: 17(1)
Pages: 62-66

Authors

Cite This Article

Andrea Müllerová, Juraj Kultan (2023). Cemiplimab in treating locally advanced NSCLC. Onkologie, 17(1), 62-66. https://doi.org/10.36290/xon.2023.014

Cemiplimab in treating locally advanced NSCLC

You May Also Like